5 results match your criteria: "Biodefense Center for Infectious and Emerging Diseases[Affiliation]"
Viruses
January 2025
Department of Avian and Rabbit Medicine, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.
The present study aims to better understand the nature of currently circulating GPV strains and their pathological impact on the immune system during natural outbreaks among different duck breeds in Egypt. For this purpose, 99 ducks (25 flocks) of different breeds, aged 14-75 days, were clinically examined, and 75 tissue pools from the thymus, bursa of Fabricius, and spleen were submitted for virus detection and identification. Clinical and postmortem findings were suggestive of GPV infection.
View Article and Find Full Text PDFVirusdisease
September 2024
Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, 11884 Egypt.
Contagious and virulent virus variants like B.1.1.
View Article and Find Full Text PDFBMC Microbiol
September 2024
Biodefense Center for Infectious and Emerging Diseases, Ministry of Defense, Cairo, Egypt.
Hum Immunol
September 2024
Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Electronic address:
Background: High-grade Epithelial Ovarian Cancer (HGEOC) is an aggressive disease that usually presents at an advanced stage. Thus, detecting the circulating cytokines (IFNγ and TNF-α) may serve as a biomarker to identify malignancy and manage therapeutic decisions.
Objectives: Assessing the clinical importance of inflammatory mediators and tumor markers in EOC Egyptian patients compared with benign cases.
Hum Immunol
July 2024
Faculty of Biotechnology, October University for Modern Sciences and Arts, MSA University, 6 October City 12451, Giza, Egypt. Electronic address:
Breast cancer (BC) continues to be the malignancy with the highest diagnosis rate worldwide. Between 15 % and 30 % of BC patients show overexpressed human epidermal growth factor receptor 2 (HER2), which is linked to poor clinical results in terms of invasiveness and recurrence risk. Passive immunity-based therapeutic approaches for treating HER2-enriched BC, are not effective and significant problems need to be tackled.
View Article and Find Full Text PDF